Skip to main content
Erschienen in: Wiener klinische Wochenschrift 21-22/2013

01.11.2013 | original article

Transperineal template-guided biopsy for diagnosis of prostate cancer in patients with at least two prior negative biopsies

verfasst von: Tobias Klatte, Natalia Swietek, Georg Schatzl, Ass.-Prof. Dr. Matthias Waldert, FEBU

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 21-22/2013

Einloggen, um Zugang zu erhalten

Summary

Objective

To evaluate the prostate cancer (PCa) detection rate, PCa location, PCa significance and complications of a standardized 24-core template-guided transperineal biopsy (TPB) approach in patients with at least two negative transrectal biopsies.

Methods

We prospectively recruited 50 men who had at least two negative transrectal ultrasound-guided extended biopsies in the past 24 months, a prostate-specific antigen (PSA) < 20 ng/mL, a prostate volume < 100 mL, and life expectancy of at least 90 % at 10 years. All patients underwent a standardized 24-core template-guided TPB biopsy. The PCa detection rate, PCa location, PCa significance, and complications were recorded.

Results

Median age was 57.5 years and the median PSA level was 7.3 ng/ml. PCa was detected in 24 patients (48 %). The anterior zone was involved in 16 (32 %) PCa. Six PCa (25 %) were insignificant. Biopsy related complications occurred in 2 patients (4 %).

Conclusions

A 24-core TPB is a safe procedure with a high PCa detection rate. Few of the detected PCa are clinically insignificant. Men with at least two negative transrectal biopsies may be counseled to undergo TPB.
Literatur
1.
Zurück zum Zitat Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2011;59(1):61–71.PubMedCrossRef Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2011;59(1):61–71.PubMedCrossRef
2.
Zurück zum Zitat Cormio L, Scattoni V, Lorusso F, Perrone A, Di Fino G, Selvaggio O, et al. Prostate cancer detection rates in different biopsy schemes. Which cores for which patients? World J Urol. 2012. doi:10.1007/s00345-012-0989-8. Cormio L, Scattoni V, Lorusso F, Perrone A, Di Fino G, Selvaggio O, et al. Prostate cancer detection rates in different biopsy schemes. Which cores for which patients? World J Urol. 2012. doi:10.1007/s00345-012-0989-8.
3.
Zurück zum Zitat Chun FK, Epstein JI, Ficarra V, Freedland SJ, Montironi R, Montorsi F, et al. Optimizing performance and interpretation of prostate biopsy: a critical analysis of the literature. Eur Urol. 2010;58(6):851–64.PubMedCrossRef Chun FK, Epstein JI, Ficarra V, Freedland SJ, Montironi R, Montorsi F, et al. Optimizing performance and interpretation of prostate biopsy: a critical analysis of the literature. Eur Urol. 2010;58(6):851–64.PubMedCrossRef
4.
Zurück zum Zitat Campos-Fernandes JL, Bastien L, Nicolaiew N, Robert G, Terry S, Vacherot F, et al. Prostate cancer detection rate in patients with repeated extended 21-sample needle biopsy. Eur Urol. 2009;55(3):600–6.PubMedCrossRef Campos-Fernandes JL, Bastien L, Nicolaiew N, Robert G, Terry S, Vacherot F, et al. Prostate cancer detection rate in patients with repeated extended 21-sample needle biopsy. Eur Urol. 2009;55(3):600–6.PubMedCrossRef
5.
Zurück zum Zitat Kawakami S, Okuno T, Yonese J, Igari T, Arai G, Fujii Y, et al. Optimal sampling sites for repeat prostate biopsy: a recursive partitioning analysis of three-dimensional 26-core systematic biopsy. Eur Urol. 2007;51(3):675–83.PubMedCrossRef Kawakami S, Okuno T, Yonese J, Igari T, Arai G, Fujii Y, et al. Optimal sampling sites for repeat prostate biopsy: a recursive partitioning analysis of three-dimensional 26-core systematic biopsy. Eur Urol. 2007;51(3):675–83.PubMedCrossRef
6.
Zurück zum Zitat Scattoni V, Raber M, Capitanio U, Abdollah F, Roscigno M, Angiolilli D, et al. The optimal rebiopsy prostatic scheme depends on patient clinical characteristics: results of a recursive partitioning analysis based on a 24-core systematic scheme. Eur Urol. 2011;60(4):834–41.PubMedCrossRef Scattoni V, Raber M, Capitanio U, Abdollah F, Roscigno M, Angiolilli D, et al. The optimal rebiopsy prostatic scheme depends on patient clinical characteristics: results of a recursive partitioning analysis based on a 24-core systematic scheme. Eur Urol. 2011;60(4):834–41.PubMedCrossRef
7.
Zurück zum Zitat Zaytoun OM, Moussa AS, Gao T, Fareed K, Jones JS. Office based transrectal saturation biopsy improves prostate cancer detection compared to extended biopsy in the repeat biopsy population. J Urol. 2011;186(3):850–4.PubMedCrossRef Zaytoun OM, Moussa AS, Gao T, Fareed K, Jones JS. Office based transrectal saturation biopsy improves prostate cancer detection compared to extended biopsy in the repeat biopsy population. J Urol. 2011;186(3):850–4.PubMedCrossRef
8.
Zurück zum Zitat Bittner N, Merrick GS, Butler WM, Bennett A, Galbreath RW. Incidence and pathologic features of prostate cancer detected on transperineal template-guided mapping biopsy following negative transrectal ultrasound-guided biopsy. J Urol. 2013. doi:10.1016/j.juro.2013.02.021. Bittner N, Merrick GS, Butler WM, Bennett A, Galbreath RW. Incidence and pathologic features of prostate cancer detected on transperineal template-guided mapping biopsy following negative transrectal ultrasound-guided biopsy. J Urol. 2013. doi:10.1016/j.juro.2013.02.021.
9.
Zurück zum Zitat Gershman B, Zietman AL, Feldman AS, McDougal WS. Transperineal template-guided prostate biopsy for patients with persistently elevated PSA and multiple prior negative biopsies. Urol Oncol. 2012. doi:10.1016/j.urolonc.2012.01.001. Gershman B, Zietman AL, Feldman AS, McDougal WS. Transperineal template-guided prostate biopsy for patients with persistently elevated PSA and multiple prior negative biopsies. Urol Oncol. 2012. doi:10.1016/j.urolonc.2012.01.001.
10.
Zurück zum Zitat Mabjeesh NJ, Lidawi G, Chen J, German L, Matzkin H. High detection rate of significant prostate tumours in anterior zones using transperineal ultrasound-guided template saturation biopsy. BJU Int. 2012;110(7):993–7.PubMedCrossRef Mabjeesh NJ, Lidawi G, Chen J, German L, Matzkin H. High detection rate of significant prostate tumours in anterior zones using transperineal ultrasound-guided template saturation biopsy. BJU Int. 2012;110(7):993–7.PubMedCrossRef
11.
Zurück zum Zitat Pal RP, Elmussareh M, Chanawani M, Khan MA. The role of a standardized 36 core template-assisted transperineal prostate biopsy technique in patients with previously negative transrectal ultrasonography-guided prostate biopsies. BJU Int. 2012;109(3):367–71.PubMedCrossRef Pal RP, Elmussareh M, Chanawani M, Khan MA. The role of a standardized 36 core template-assisted transperineal prostate biopsy technique in patients with previously negative transrectal ultrasonography-guided prostate biopsies. BJU Int. 2012;109(3):367–71.PubMedCrossRef
12.
Zurück zum Zitat Walz J, Gallina A, Saad F, Montorsi F, Perrotte P, Shariat SF, et al. A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. J Clin Oncol. 2007;25(24):3576–81.PubMedCrossRef Walz J, Gallina A, Saad F, Montorsi F, Perrotte P, Shariat SF, et al. A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. J Clin Oncol. 2007;25(24):3576–81.PubMedCrossRef
13.
Zurück zum Zitat Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL. The International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol. 2005;29(9):1228–42. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL. The International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol. 2005;29(9):1228–42.
14.
Zurück zum Zitat Epstein JI, Sanderson H, Carter HB, Scharfstein DO. Utility of saturation biopsy to predict insignificant cancer at radical prostatectomy. Urology. 2005;66(2):356–60.PubMedCrossRef Epstein JI, Sanderson H, Carter HB, Scharfstein DO. Utility of saturation biopsy to predict insignificant cancer at radical prostatectomy. Urology. 2005;66(2):356–60.PubMedCrossRef
15.
Zurück zum Zitat Oon SF, Watson RW, O’Leary JJ, Fitzpatrick JM. Epstein criteria for insignificant prostate cancer. BJU Int. 2011;108(4):518–25.PubMedCrossRef Oon SF, Watson RW, O’Leary JJ, Fitzpatrick JM. Epstein criteria for insignificant prostate cancer. BJU Int. 2011;108(4):518–25.PubMedCrossRef
16.
Zurück zum Zitat Klatte T, Waldert M, de Martino M, Schatzl G, Mannhalter C, Remzi M. Age-specific PCA3 score reference values for diagnosis of prostate cancer. World J Urol. 2012;30(3):405–10.PubMedCrossRef Klatte T, Waldert M, de Martino M, Schatzl G, Mannhalter C, Remzi M. Age-specific PCA3 score reference values for diagnosis of prostate cancer. World J Urol. 2012;30(3):405–10.PubMedCrossRef
Metadaten
Titel
Transperineal template-guided biopsy for diagnosis of prostate cancer in patients with at least two prior negative biopsies
verfasst von
Tobias Klatte
Natalia Swietek
Georg Schatzl
Ass.-Prof. Dr. Matthias Waldert, FEBU
Publikationsdatum
01.11.2013
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 21-22/2013
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-013-0421-4

Weitere Artikel der Ausgabe 21-22/2013

Wiener klinische Wochenschrift 21-22/2013 Zur Ausgabe

mitteilungen der gesellschaft

Die Österreichische Apheresegesellschaft

MUW researcher of the month

Researcher of the Month